Skip to Content

Tyra Biosciences Inc TYRA

Morningstar Rating
$16.40 +0.10 (0.61%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TYRA is trading at a 33% discount.
Price
$16.51
Fair Value
$74.11
Uncertainty
Extreme
1-Star Price
$754.78
5-Star Price
$8.88
Economic Moat
Mhln
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TYRA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.30
Day Range
$15.8416.78
52-Week Range
$10.3820.67
Bid/Ask
$11.12 / $26.23
Market Cap
$861.35 Mil
Volume/Avg
128,535 / 121,167

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
38

Comparables

Valuation

Metric
TYRA
CLDX
CGEM
Price/Earnings (Normalized)
Price/Book Value
3.435.441.68
Price/Sales
294.16
Price/Cash Flow
Price/Earnings
TYRA
CLDX
CGEM

Financial Strength

Metric
TYRA
CLDX
CGEM
Quick Ratio
13.2713.6916.60
Current Ratio
13.8013.8717.07
Interest Coverage
Quick Ratio
TYRA
CLDX
CGEM

Profitability

Metric
TYRA
CLDX
CGEM
Return on Assets (Normalized)
−22.50%−30.49%−24.60%
Return on Equity (Normalized)
−23.73%−33.19%−25.95%
Return on Invested Capital (Normalized)
−27.79%−32.85%−29.67%
Return on Assets
TYRA
CLDX
CGEM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWhgfhdgzpYgyv$571.0 Bil
VRTX
Vertex Pharmaceuticals IncQcbhshbvPfyvvm$107.8 Bil
REGN
Regeneron Pharmaceuticals IncGmyhxfwtYszwz$106.1 Bil
MRNA
Moderna IncGkspvzgDlfnx$42.3 Bil
ARGX
argenx SE ADRDsdmthlpfVwbwf$23.7 Bil
BNTX
BioNTech SE ADRTlrpwnhfCwrc$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncGsjdqsqyPcjwlw$19.4 Bil
BMRN
Biomarin Pharmaceutical IncLyydzlxlPmngxf$16.7 Bil
RPRX
Royalty Pharma PLC Class AGvbqvtgkvJbvchyc$13.6 Bil
INCY
Incyte CorpYzbzgprTdjms$12.8 Bil

Sponsor Center